In a strategic collaboration, EV Biotech and Synonym have announced a powerful alliance, merging their distinct expertise to expedite the advancement and market entry of groundbreaking biomaterials. This partnership represents a significant step forward in the biomaterial sector, leveraging the strengths of both entities to foster innovation and efficiency.
EV Biotech’s pioneering platform is designed around computational prediction and experimental validation, enabling the swift creation and refinement of microbial strains for biomaterial production. This technology provides Synonym’s clientele with direct access to advanced biomanufacturing capabilities, substantially accelerating the crucial phases of scaling up production and achieving commercial success. By utilizing EV Biotech’s innovative approach, companies can optimize their biomaterial development process from the outset.
Conversely, Synonym’s customer base will gain access to EV Biotech’s cutting-edge technology, unlocking significant reductions in strain engineering expenses and compressing time-to-market cycles. This synergy empowers businesses to attain superior R&D outcomes, streamlining the path from laboratory innovation to industrial application. The partnership, acting as a catalyst, is set to redefine industry benchmarks.
This cooperative framework cultivates a beneficial ecosystem, driving the biomaterial industry towards progress by shortening development timelines and lowering associated costs. Optimizing biomaterial production through state-of-the-art strain engineering and accelerating the commercialization of innovative biomaterials are central to this joint venture. This strategic liaison marks a pivotal move towards transforming the biomaterial landscape, paving the way for sustainable and inventive solutions across diverse sectors through their combined proficiency.
NZE-Renewables banner ad promoting sustainable energy solutions for a greener future
According to Joshua Lachter, Co-Founder and Chief Business Officer at Synonym, “For bioproducts to seamlessly integrate into our daily lives, precision is essential for companies right from the initial stages of strain development. EV Biotech’s state-of-the-art computational design technology empowers companies to enhance strain performance, effectively reducing their R&D time by half and accelerating their time to market.” This partnership, in essence, is about creating efficiency and speed.
Linda Dijkshoorn, Chief Commercial Officer (CCO) and Founder of EV Biotech, further emphasizes the mutual benefits, stating, “Synonym’s expertise in techno-economic analysis, lifecycle assessment, and facility development and financing will help our customers commercialize faster, cheaper, and more sustainably. We are excited to help more companies scale up successfully by identifying their commercial bioprocess milestones through Synonym’s platform and helping them reach their strain and fermentation targets using ours.” This alliance underscores a shared vision for a more efficient and sustainable biomaterial industry.
